SCHEMBL5344833

SCHEMBL5344833

CCOC(=O)c1cc(-c2ccc(OC)cc2)sc1N

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.78
ALDH1A1 P00352 7/20 0.78
GAA P10253 7/20 0.78
SMN1; SMN2 Q16637 7/20 0.78
RAB9A P51151 6/20 0.78
MEN1 O00255 5/20 0.78
KMT2A Q03164 5/20 0.78
NPC1 O15118 5/20 0.78
HSD17B10 Q99714 4/20 0.78
ALOX15 P16050 2/20 0.78
LMNA P02545 2/20 0.78
HPGD P15428 6/20 0.74
KDM4E B2RXH2 5/20 0.70
TP53 P04637 1/20 0.70
CASP3 P42574 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
GRM6 O15303 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8207063 0.88 ALDH1A1 (0.84) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL4224451 0.86 MAPT (0.74) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL656187 0.85 MAPT (0.80) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL654015 0.85 ALDH1A1 (1.00) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL16689457 0.84 MAPT (0.78) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL10725054 0.83 MAPT (1.00) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL610929 0.83 ALDH1A1 (0.76) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL4212681 0.82 ALDH1A1 (0.67) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL1693702 0.80 MAPT (0.71) MAPTALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL5864713 0.80 GAA (0.63) MAPTALDH1A1GAASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864312-B1 NOVEL ANTI-CANCER THIOPHENE COMPOUNDS UNIV LEUVEN KATH (BE) 2021-09-22 EP disclosed
US-9278958-B2 Anti-cancer compounds KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) 2016-03-08 US disclosed
US-20150126559-A1 NOVEL ANTI-CANCER COMPOUNDS UNIVERSITA DEGLI STUDI DI FERRARA (IT) 2015-05-07 US disclosed
WO-2007102679-A1 NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME JE IL PHARMACEUTICAL CO., LTD. (KR) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126559-A1 NOVEL ANTI-CANCER COMPOUNDS ATP5F1A, TP53, ABCF1 MAPT 4801/4885ALDH1A1 266/4885GAA 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.